Bioavailability of DHA-TG (Docosahexaenoic Triglyceride), DHA-PC (Docosahexaenoic Phosphatidylcholine) and AcedoPC (1-acetyl-2-docosahexaenoic-glycerophosphocholine) in Human
Trial Snapshot
- Phase
- Not Applicable
- Status
- Completed
- Sponsor
- Hospices Civils de Lyon
- Enrollment
- 4
- Locations
- 1
- Primary Endpoint
- Concentration of 13C-DHA in red blood cells
Study Overview
Brief Summary
The purpose of this study is to compare three lipidic forms of DHA in their metabolic pathway in human by using 13C labeled molecules.
The circulating form of DHA plays a major role in his cerebral incorporation. The aim of this research is to confirm that some lipidic forms are best carriers for the cerebral incorporation in studying 13C-DHA distribution in plasma lipids and blood cells.
Study Design
- Study Type
- Interventional
- Allocation
- Randomized
- Intervention Model
- Crossover
- Primary Purpose
- Basic Science
- Masking
- Double (Participant, Investigator)
Eligibility Criteria
- Ages
- 60 Years to 70 Years (Adult, Older Adult)
- Sex
- Male
- Accepts Healthy Volunteers
- Yes
Inclusion Criteria
- •Healthy male
- •Aged of 60 to 70 years
- •Body Mass Index of 20 to 30 kg/m2
- •Glycaemic and lipid parameters normal
Exclusion Criteria
- •Smokers more than ten cigarettes/day
- •Medical history of personal or family dyslipidemia
- •Medication that could interfere with lipid metabolism
Arms & Interventions
13-C labeled PC-DHA
Intervention: 13-C labeled AceDoPC-DHA (Drug)
13-C labeled PC-DHA
Intervention: 13-C labeled TG-DHA (Drug)
13-C labeled PC-DHA
Intervention: 13-C labeled PC-DHA (Drug)
13-C labeled TG-DHA
Intervention: 13-C labeled AceDoPC-DHA (Drug)
13-C labeled TG-DHA
Intervention: 13-C labeled TG-DHA (Drug)
13-C labeled TG-DHA
Intervention: 13-C labeled PC-DHA (Drug)
13-C labeled AceDoPC-DHA
Intervention: 13-C labeled AceDoPC-DHA (Drug)
13-C labeled AceDoPC-DHA
Intervention: 13-C labeled TG-DHA (Drug)
13-C labeled AceDoPC-DHA
Intervention: 13-C labeled PC-DHA (Drug)
Outcomes
Primary Outcomes
Concentration of 13C-DHA in red blood cells
Time Frame: At Day 1
6 hours after product ingestion
Secondary Outcomes
- Concentration of 13C-DHA in plasma lipids(At Day 1)
- Concentration of 13C-DHA in platelets(At Day 1)